Market capitalization | $2.36m |
Enterprise Value | $21.86m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Sales growth (TTM) Sales growth | -100.00% |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-9.30m |
Free cash flow (TTM) Free cash flow | $-9.74m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
1 Analyst has issued a forecast NEMAURA MEDICAL INC:
1 Analyst has issued a forecast NEMAURA MEDICAL INC:
Dec '23 |
+/-
%
|
||
Turnover | - - |
-
|
|
Gross income | -0.49 -0.49 |
133%
133%
|
|
EBITDA | -8.82 -8.82 |
5%
5%
|
EBIT (operating result) EBIT | -9.30 -9.30 |
6%
6%
|
Net profit | -11 -11 |
19%
19%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Nemaura Medical, Inc. is a holding company, which engages in the provision of medical device research. Through its subsidiaries, it manufactures and commercializes continuous glucose monitoring system, named sugarBEAT. The sugarBEAT is consist of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five minute intervals with the use of a mobile app. The company was founded by Dewan Fazlul Hoque Chowdhury on December 24, 2013 and is headquartered in Loughborough, the United Kingdom.
Head office | United States |
CEO | Dewan Chowdhury |
Employees | 38 |
Founded | 2013 |
Website | www.nemauramedical.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.